Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial

Jonathan D. Schoenfeld*, Glenn J. Hanna, Vickie Y. Jo, Bhupendra Rawal, Yu Hui Chen, Paul S. Catalano, Ana Lako, Zoe Ciantra, Jason L. Weirather, Shana Criscitiello, Adrienne Luoma, Nicole Chau, Jochen Lorch, Jason I. Kass, Donald Annino, Laura Goguen, Anupam Desai, Brendan Ross, Hina J. Shah, Heather A. JaceneDanielle N. Margalit, Roy B. Tishler, Kai W. Wucherpfennig, Scott J. Rodig, Ravindra Uppaluri, Robert I. Haddad

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Fingerprint

Dive into the research topics of 'Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences